Watchlist Price Alert

TG Therapeutics Inc. (TGTX)

NASDAQ: TGTX · Real-Time Price · USD

37.81

-5.63 (-12.96%)

At close: May 05, 2025, 3:59 PM

37.68

-0.36%

After-hours: May 05, 2025, 07:58 PM EDT

-12.96% (1D)

Bid	37.22
Market Cap	6B
Revenue (ttm)	329M
Net Income (ttm)	23.38M
EPS (ttm)	0.15
PE Ratio (ttm)	252.1
Forward PE	23.53
Analyst	Buy

Ask	37.94
Volume	11,667,820
Avg. Volume (20D)	2,790,666
Open	40.80
Previous Close	43.44
Day's Range	35.62 - 45.37
52-Week Range	15.16 - 46.48
Beta	2.14

About TGTX

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbra...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date May 3, 2010

Employees 338

Stock Exchange NASDAQ

Ticker Symbol TGTX

Website https://www.tgtherapeutics.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for TGTX stock is "Buy." The 12-month stock price forecast is $43, which is an increase of 13.71% from the latest price.

Stock Forecasts

Earnings Surprise

New

TG Therapeutics has released their quartely earnings on May 5, 2025:

Revenue of $120.86M exceeds estimates by $3M, with 90.40% YoY growth.

EPS of 0.03 misses estimates by -0.14, with 142.86% YoY growth.

Next Earnings Release

TG Therapeutics Inc. is scheduled to release its earnings on May 5, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 day ago New

-13.26%

TG Therapeutics shares are trading lower after the... Unlock content with Pro Subscription

2 months ago

+14.39%

TG Therapeutics shares are trading higher after the company reported better-than-expected Q4 sales results.

News

22 hours ago · benzinga.com

TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show

TG Therapeutics Inc TGTX on Monday reported first-quarter earnings per share of 3 cents, a shift from a loss of 7 cents a year ago, but below the consensus of 17 cents.

23 hours ago · fool.com

Why TG Therapeutics Stock Was Tumbling Today

A near-doubling of revenue and a flip into profitability on the bottom line apparently weren't good enough for TG Therapeutics (TGTX -12.32%) shareholders on Monday.

1 day ago · seekingalpha.com

TG Therapeutics: Share Price Slip On Q1 Earnings Unsurprising Given Challenges

TG Therapeutics' Q1 2025 earnings report showed strong revenue growth, with Briumvi net revenues rising to $119.7m, prompting an increase in full-year revenue guidance. Despite a >15% drop in stock va...

16 hours ago · seekingalpha.com

TG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript

TG Therapeutics, Inc. (NASDAQ:TGTX ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants Jenna Bosco - Chief Communications Officer Michael Weiss - Chairman and Chief Executiv...

17 hours ago · zacks.com

TG Therapeutics (TGTX) Lags Q1 Earnings Estimates

TG Therapeutics (TGTX) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to loss of $0.07 per share a year ago.

6 days ago · zacks.com

TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago · zacks.com

TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why

Strong adoption of TGTX's sole marketed product, Briumvi, approved for treating relapsing forms of multiple sclerosis, is driving the top line.

1 month ago · investors.com

These Insurance Stocks And Biotech Leader Hit New Highs As Stock Market Crumbles

Insurance stock Root soared to a new high on Friday. The IBD 50 holding has an ideal Composite and Relative Strength Rating.

1 month ago · benzinga.com

Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher

Trading is subdued with TG Therapeutics, Inc. TGTX on Friday. But the shares remain in an uptrend and there is a good chance the trend will continue.

1 month ago · zacks.com

Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?

TG Therapeutics (TGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increa...

Load More News